ML for Hematological Diagnosis

• Machine learning for hematological diagnosis is defined as the application of computational models to analyze blood counts and cellular morphology for accurate disease classification.
• Techniques such as random forests, CNNs, and transformers achieve high precision, with metrics reaching up to 97% accuracy and maintaining fairness across demographic subgroups.
• Hybrid methods that combine expert knowledge with deep and classical learning facilitate low-data adaptation and improved interpretability for disorders like leukemia and anemia.

Machine learning for hematological diagnosis encompasses algorithmic approaches that utilize tabular laboratory data and digital cellular morphology to support or automate disease classification in hematology. This field covers a spectrum from blood count–driven models for broad disease differentiation to deep neural networks for fine-grained cytomorphological analysis, and hybrid frameworks that incorporate expert knowledge, ethics, and domain transfer. The integration of statistical learning, representation learning, domain alignment, and clinical fairness principles has enabled consistently high performance across disorders such as leukemias, anemias, immune cytopenias, and laboratory triage problems.

1. Data Types, Cohort Construction, and Feature Engineering

Hematological diagnostic machine learning leverages heterogeneous data modalities:

• Tabular Data: Complete blood counts (CBC), differential counts, selected biochemistry values, and demographic variables form the basis for many diagnostic models. For example, random forests trained on 43 ICD-coded diseases and up to 181 laboratory variables can achieve top-1 prediction accuracy of 0.59 and top-5 of 0.88, equivalent to the performance of subspecialty-trained hematologists (Gunčar et al., 2017) (see Table 1 in cited work).
• Digital Microscopy: High-resolution images of blood smears and bone marrow aspirates are employed for cell detection, segmentation, classification, and construction of whole-slide or patient-level fingerprints, such as the Histogram of Cell Types (HCT) (Tayebi et al., 2021).
• Multi-modal Fusion: Joint modeling of image-based features and clinical laboratory values is increasingly represented in transformer-based and ensemble pipelines (Dasdelen et al., 23 Sep 2025, Ameen et al., 2024).

Data cleaning, missing-value imputation (e.g., median imputation for blood variables with <5% missingness), normalization (min–max scaling or standardization), and categorical encoding (one-hot for race/gender) are standard preprocessing steps (Miah et al., 2024). Clinical datasets typically undergo exclusion of confounders and incomplete cases to reduce bias.

2. Algorithmic Frameworks: Classical Models, Deep Learning, and Hybrid Approaches

A variety of algorithmic paradigms are employed:

• Classical Statistical and Tree-based Models:
  • Logistic Regression, SVM, k-NN, Decision Tree, Random Forest: Used extensively for tabular CBC-driven diagnosis. In immune thrombocytopenia (ITP) discrimination, a random forest achieved F1 ≈ 100% and AUC ≈ 1.00, with perfect fairness parity across demographic subgroups (Miah et al., 2024).
  • Fuzzy Logic Integration: Fuzzy logic–infused pipelines use expert-derived rules and membership functions for subtle class boundaries in CBC data, with subsequent random forest classification. This yielded 97% accuracy in 11-class disease discrimination (Ameen et al., 2024).
  • Gradient Boosted Trees (XGBoost): A preferred algorithm for flow cytometry and COVID-19 triage due to its handling of high-dimensional, imbalanced, and partially observed data (Kang et al., 2021, Kukar et al., 2020).
• Deep Learning Pipelines:
  • CNNs on Blood/Bone Marrow Smears: Image-based classification models, ranging from custom 7-layer CNNs (Ahmed et al., 2022) to hybrid ensembles fusing VGG, ResNet, and Inception backbones (Mattapalli et al., 2021), consistently surpass 90–97% accuracy.
  • Multiple-Instance Learning (MIL): Weakly supervised approaches associate patient labels with bags of detected cell crop features, enabling classification of rare leukemias (APL, ALL) without single-cell ground truth (Manescu et al., 2022, Farsangi et al., 2023).
  • Transformer and Attention-based Architectures: Recent models aggregate per-cell embeddings with attention-based pooling to yield slide- or patient-level predictions and enable explicit attention visualization. The cAItomorph transformer pipeline demonstrated 68% overall accuracy (top-2: 84%) on real-world blood smear data and achieved 0.74 F1 for acute leukemia at high sensitivity (Dasdelen et al., 23 Sep 2025).
  • Self-supervised and Contrastive Learning: Methods such as SwAV and supervised contrastive learning produce robust cytomorphological representations from large, unlabeled datasets, with SwAV + linear head yielding macro-F1 = 0.73 in 21-class marrow cell recognition (Fazeli et al., 2022).
• Hybrid and Low-data Regimes:
  • CNN + Classical ML: Deep representations coupled with SVM or XGBoost classifiers maintain high performance in low-data scenarios. For RBC/WBC/erythroblast differentiation, ResNet-50 with frozen weights plus SVM achieves 86.75% accuracy and 98.9% erythroblast precision with only 1% of data (Goswami et al., 2024).
  • Active Learning and Domain Adaptation: Annotation costs are ameliorated via annotation-efficient pipelines and loss formulations (e.g., BoDA for domain alignment across scanners/stains), which preserve macro-F1 under domain shift (Umer et al., 2023, Tayebi et al., 2021).

3. Model Training, Validation, and Evaluation Metrics

Training protocols align with best practices in ML for tabular and vision data:

• Stratified Cross-validation: Ensures balanced outcome and subgroup representation in training/validation splits; 5-fold or 10-fold schemes predominate (Miah et al., 2024, Gunčar et al., 2017).
• Hyperparameter Tuning: Grid search across classifier-specific options (e.g., SVM kernels and slack, random forest depth/features, CNN layer size) is standard.
• Loss Functions and Class Imbalance Measures: Cross-entropy is default; Focal Loss is used to address class imbalance in deep architectures (Maruf et al., 24 Aug 2025). Fuzzy logic pipelines incorporate min–max and centroid defuzzification.
• Performance Metrics: Standard metrics include precision, recall, F1-score, accuracy, and AUC–ROC. Fairness is explicitly measured by Equalized Odds (EO) (Miah et al., 2024). MIL and multi-class settings report per-class F1 and macro/micro averaging.
• Explainability and Interpretability: Feature importance via permutation, SHAP values, and visualization of rule/expert-derived decision trees underpins clinical trust.

Model or Pipeline	Data Modality	Accuracy/F1	Minimum Data Regime	Notable Metric	Reference
Random Forest	CBC/Tabular	F1 ≈ 100%	N = 150	EO = 1.00	(Miah et al., 2024)
CNN (7-layer)	Blood smear images	97.3% accuracy	587 images	F1 (cancerous) = 0.96	(Ahmed et al., 2022)
Transformer+ViT (cAItomorph)	Blood smear, ~1M images	67.6% acc, F1 = 0.68	>1M images	F1 (acute leukemia)= 0.74	(Dasdelen et al., 23 Sep 2025)
ResNet-50 + SVM	Erythroblast/WBCs images	86.8% accuracy*	1% of data	Erythroblast precision=0.99	(Goswami et al., 2024)
MIL (MILLIE)	APL/ALL detection	AUC = 0.94–0.99	200–1000 cells	Weak supervision	(Manescu et al., 2022)

*Low-data regime, 168 images/class

4. Key Findings in Feature Importance and Clinical Relevance

Permutation and tree-based importance consistently identify clinically meaningful variables:

• Platelet Count Dominance: For ITP discrimination, platelet count (dx_plt_ct) yielded ΔF1 up to 0.30 when shuffled, signifying the alignment of ML importance with clinical intuition (Miah et al., 2024).
• Composite Markers: In COVID-19 diagnosis, mean corpuscular hemoglobin concentration, eosinophil count, and albumin were the most predictive among 35 routine labs (Kukar et al., 2020).
• Cytomorphological Context: Attention mechanisms in transformer architectures robustly highlight biologically relevant regions (e.g., nucleus-cytoplasm ratios, giant platelets), and their visualization delivers case-based explanations (Dasdelen et al., 23 Sep 2025).
• Hybrid Reasoning: Fuzzy logic rules integrating boundary expert knowledge enable models to discriminate subtle syndromes (e.g., distinguishing IDA/SCA/ABL by “Normal” WBC/HGB/HCT/PLT) (Ameen et al., 2024).

5. Fairness, Interpretability, and Deployment Considerations

• Fairness-Accuracy Trade-off: Demographic-unaware models may maximize accuracy by relying on strong clinical signals but induce subgroup disparities; demographic-aware models distribute decision weights to improve equalized odds at some accuracy cost in certain classifiers (Miah et al., 2024).
• Interpretability: Decision trees and single-feature rules are directly interpretable by clinicians (e.g., “if plt < 25×10^9/L → ITP”), while ensemble and DNN models require SHAP or attention visualization overlays.
• Clinical Integration: Inference times on consumer GPUs range from <30 ms/image for VGG19+MHSA pipelines (Maruf et al., 24 Aug 2025) to several seconds for whole-slide ROI/cell detection and HCT construction (Tayebi et al., 2021). Minimal retraining is required for transfer to new labs or scanning protocols when using domain-aligned representations or MIL.
• Regulatory and Practical Aspects: Most models emphasize external cohort validation, modular deployment architectures (cloud or on-premise API), and explicit checkpoints for interpretability.

6. Extensions to Other Hematologic Disorders and Generalization

• Disease Scope: ML pipelines generalize beyond rare cytopenias and leukemias to multi-class diagnosis of anemia, platelet disorders, viral and bacterial infection triage, and bone marrow dysplasias (Gunčar et al., 2017, Ameen et al., 2024).
• Low-data Adaptation: Hybrid architectures (CNN+SVM, feature-extractor + XGBoost) enable high performance even with <5% of data, suited to rare conditions or resource-limited settings (Goswami et al., 2024).
• Domain-Robustness: Techniques such as BoDA loss (Umer et al., 2023) and self-supervised representation learning (Fazeli et al., 2022) robustly handle variation in staining, scanner, and image resolution, with macro-F1 maintained >0.40 even in OOD test domains.

7. Recommendations and Future Directions

To maximize the utility and clinical integration of machine learning in hematological diagnosis:

• Prioritize collection of balanced, multi-institutional datasets with comprehensive clinical feature sets and image modalities.
• Employ tree-based or ensemble models for workflows where joint accuracy–fairness is required; explicate fairness metrics such as Equalized Odds during validation (Miah et al., 2024).
• Favor architectures enabling interpretability—via rule extraction, feature attribution, or attention heatmaps—to facilitate clinical trust and regulatory compliance.
• Investigate MIL and hybrid feature–knowledge–driven frameworks for low-annotation or rare-disease regimes.
• Pursue methods robust to domain variability (domain-adaptive losses, self-supervision) and integrate with clinical decision support systems for broader impact.

By adhering to these principles, ML-augmented hematological diagnosis offers not only statistical accuracy but also clinical alignment, transparency, and scalability across global laboratory contexts (Miah et al., 2024, Gunčar et al., 2017, Zolfaghari et al., 2023, Tayebi et al., 2021, Mattapalli et al., 2021).